First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer

First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer
VBL Therapeutics has successfully administered the initial dose to the first patient in its Phase 3 trial investigating the effects of VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer. The pivotal OVAL trial (NCT03398655), currently recruiting adult patients, will compare the effectiveness of VB-111 and Taxol (paclitaxel) against Taxol alone in women who failed to respond to

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *